Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 14/20 | 0.97 |
| ▸ | DRD3 known ✓ | P35462 | 13/20 | 0.67 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.62 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.62 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.62 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.62 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.62 |
| ▸ | HTR7 known ✓ | P34969 | 2/20 | 0.62 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.62 |
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.62 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.62 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.62 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.62 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.62 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.62 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.62 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.62 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.62 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.62 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3177580 | 1.00 | DRD2 (0.97) | DRD2DRD3HTR1AADRA2ADRD4 | |
| Hydrochloric Acid SCHEMBL30224993 | 1.00 | DRD2 (0.97) | DRD2DRD3HTR1AADRA2ADRD4 | |
| Hydrochloric Acid SCHEMBL29502145 | 1.00 | DRD2 (0.97) | DRD2DRD3HTR1AADRA2ADRD4 | |
| Hydrochloric Acid SCHEMBL28714264 | 1.00 | DRD2 (0.97) | DRD2DRD3HTR1AADRA2ADRD4 | |
| Hydrochloric Acid SCHEMBL3407353 | 1.00 | DRD2 (0.97) | DRD2DRD3HTR1AADRA2ADRD4 | |
| Hydrochloric Acid SCHEMBL28714263 | 1.00 | DRD2 (0.97) | DRD2DRD3HTR1AADRA2ADRD4 | |
| Hydrochloric Acid SCHEMBL3407356 | 1.00 | DRD2 (0.97) | DRD2DRD3HTR1AADRA2ADRD4 | |
| Hydrochloric Acid SCHEMBL1301802 | 0.99 | DRD2 (0.95) | DRD2DRD3HTR1AADRA2ADRD4 | |
| Hydrochloric Acid SCHEMBL29171676 | 0.99 | DRD2 (0.95) | DRD2DRD3HTR1AADRA2ADRD4 | |
| SCHEMBL2034152 | 0.99 | DRD2 (1.00) | DRD2DRD3HTR1AADRA2ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111333596-A | Preparation method of cariprazine key intermediate | 北京万全德众医药生物技术有限公司 | 2020-06-26 | — | — | CN | claimed |
| US-7473692-B2 | Sulfonamide derivatives as D3-receptor ligands | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2009-01-06 | — | — | US | claimed |
| CN-114262283-B | Method for preparing kali lazine and intermediate thereof | 苏州旺山旺水生物医药有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-RE49302-E1 | Pharmaceutical formulations containing dopamine receptor ligands | RICHTER GEDEON NYRT. (HU) | 2022-11-15 | — | — | US | disclosed |
| US-RE49110-E1 | Pharmaceutical formulations containing dopamine receptor ligands | RICHTER GEDEON NYRT. | 2022-06-21 | — | — | US | disclosed |
| CN-111320593-B | Refining method of high-purity Carilazine | 江苏恩华药业股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-114262283-A | Method for preparing cariprazine and intermediate thereof | 苏州旺山旺水生物医药有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-11273156-B2 | Stable cariprazine formulations for oral use | AUROBINDO PHARMA LTD (IN) | 2022-03-15 | — | — | US | disclosed |
| CN-111333596-A | Preparation method of cariprazine key intermediate | 北京万全德众医药生物技术有限公司 | 2020-06-26 | — | — | CN | disclosed |
| CN-111333596-A | Preparation method of cariprazine key intermediate | 北京万全德众医药生物技术有限公司 | 2020-06-26 | — | — | CN | disclosed |
| CN-111320593-A | Refining method of high-purity Carilazine | 江苏恩华药业股份有限公司 | 2020-06-23 | — | — | CN | disclosed |
| EP-2367807-B1 | PROCESS FOR THE PREPARATION OF PIPERAZINE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2013-02-13 | — | — | EP | disclosed |
| EP-1438302-B1 | NEW SULFONAMIDE DERIVATIVES AS D3-RECEPTOR LIGANDS | RICHTER GEDEON NYRT (HU) | 2012-05-30 | — | — | EP | disclosed |
| US-20110269959-A1 | PROCESS FOR THE PREPARATION OF PIPERAZINE DERIVATIVES | GEDEON RICHTER NYRT. (HU) | 2011-11-03 | — | — | US | disclosed |
| EP-2367807-A1 | PROCESS FOR THE PREPARATION OF PIPERAZINE DERIVATIVES | Richter Gedeon Nyrt. (HU) | 2011-09-28 | — | — | EP | disclosed |
| EP-2317852-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING DOPAMINE RECEPTOR LIGANDS | Forest Laboratories Holdings Limited (BM) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010070371-A1 | PROCESS FOR THE PREPARATION OF PIPERAZINE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010009309-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING DOPAMINE RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016334-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING DOPAMINE RECEPTOR LIGANDS | RICHTER GEDEON NYRT. (HU) | 2010-01-21 | — | — | US | disclosed |
| US-20050107397-A1 | Sulfonamide derivatives as d3-receptor agonists | RICHTER GEDEON VEGYESZETI GYAR RT. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016334-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING DOPAMINE RECEPTOR LIGANDS | PRLHR, SLC6A3, SLC18A2 | DRD2 30/4885DRD3 93/4885HTR1A 17/4885 |
| US-20110269959-A1 | PROCESS FOR THE PREPARATION OF PIPERAZINE DERIVATIVES | GPKOW, CAT, KCNH2 | DRD2 1201/4885DRD3 2055/4885HTR1A 1327/4885 |
| US-20050107397-A1 | Sulfonamide derivatives as d3-receptor agonists | SLC6A3, DRD3, GPR3 | DRD2 8/4885DRD3 2/4885HTR1A 86/4885 |
| US-11273156-B2 | Stable cariprazine formulations for oral use | PDE12, CYP3A5, HDAC5 | DRD2 190/4885DRD3 313/4885HTR1A 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.